Revvity (NYSE:RVTY) Releases Quarterly Earnings Results, Beats Expectations By $0.08 EPS

Revvity (NYSE:RVTY) posted its earnings results on Tuesday. The company reported $1.38 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.30 by $0.08, Zacks reports. Revvity had a return on equity of 8.64% and a net margin of 8.61%. The company had revenue of $728.90 million for the quarter, compared to analysts’ expectations of $694.73 million. During the same period last year, the firm earned $1.18 earnings per share. Revvity’s quarterly revenue was up 4.3% on a year-over-year basis.

Here are the key takeaways from Revvity’s conference call:

• Revvity exceeded expectations in Q3, delivering 7% pro forma organic growth, 29.4% adjusted operating margins, and adjusted EPS of $1.37, $0.08 above the midpoint of its guidance.
• Life sciences organic growth reached 9%, led by high-single-digit reagent growth, mid-single-digit instrument growth, and upper-teens Signals Software growth. Management cited improving pharma and biotech demand, expanding AI-related activity, and growing instrument backlogs, particularly in high-content screening.
• The company raised its full-year outlook to approximately 5% pro forma organic growth and $5.40–$5.45 adjusted EPS, while increasing its operating-margin forecast to 28.8%. Efficiency initiatives and favorable mix are supporting more than 40% incremental margins.
• Diagnostics grew 5% organically, with margins reaching 29.9%; excluding the China immunodiagnostics business targeted for divestiture, margins exceeded 30%. Revvity also launched a type 1 diabetes screening assay in Europe, but reproductive health remains constrained by weak Chinese birth rates.
• Management expects some moderation in Q4 growth, partly because reagent bulk orders shifted into Q3 and Signals Software growth is expected to slow from the high teens to the mid-teens. AI demand is broadening but remains in its early stages, and the company expects no share repurchases in its Q4 guidance.

Revvity Stock Performance

Shares of RVTY stock opened at $159.68 on Thursday. The company’s fifty day moving average price is $146.58 and its 200-day moving average price is $112.84. The stock has a market cap of $17.82 billion, a PE ratio of 29.46, a price-to-earnings-growth ratio of 2.95 and a beta of 1.08. The company has a current ratio of 2.65, a quick ratio of 1.50 and a debt-to-equity ratio of 0.36. Revvity has a 12 month low of $81.22 and a 12 month high of $171.74.

Revvity Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Friday, February 12th. Stockholders of record on Friday, January 22nd will be issued a dividend of $0.07 per share. This represents a $0.28 dividend on an annualized basis and a dividend yield of 0.2%. The ex-dividend date is Friday, January 22nd. Revvity’s payout ratio is 13.33%.

Insider Activity

In related news, insider Maxwell Krakowiak sold 1,631 shares of Revvity stock in a transaction dated Monday, September 21st. The shares were sold at an average price of $144.53, for a total transaction of $235,728.43. Following the completion of the transaction, the insider directly owned 14,781 shares of the company’s stock, valued at $2,136,297.93. This trade represents a 9.94% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, insider Tajinder Vohra sold 7,330 shares of the business’s stock in a transaction dated Wednesday, September 16th. The stock was sold at an average price of $140.88, for a total transaction of $1,032,650.40. Following the sale, the insider directly owned 6,635 shares in the company, valued at $934,738.80. The trade was a 52.49% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last quarter, insiders sold 9,045 shares of company stock valued at $1,281,439. 0.85% of the stock is owned by company insiders.

Key Headlines Impacting Revvity

Here are the key news stories impacting Revvity this week:

• Positive Sentiment: Revvity reported Q3 adjusted EPS of $1.38, above the roughly $1.30 consensus, and revenue of $728.9 million versus estimates of $694.7 million. Revenue grew 4.3% year over year, with Life Sciences strength and margin expansion cited as drivers. The company also raised its annual outlook, helping spark a sharp initial share-price jump and a new one-year high. Read the Q3 results and outlook article
• Positive Sentiment: Several analysts raised their price targets after the results. TD Cowen lifted its target to $185 and kept a Buy rating; Barclays raised its target to $175, and RBC increased its target to $172. CFRA also upgraded the stock from Hold to Buy. Read TD Cowen analyst information
• Neutral Sentiment: JPMorgan raised its target from $155 to $160 but maintained a Neutral rating, indicating a more cautious view on near-term upside. Read the analyst update
• Negative Sentiment: After the earnings-driven surge, investors may be taking profits. A recent article also questioned whether the stock is now too expensive, which could temper enthusiasm even as analysts raise targets. Read the valuation and dividend article

Analyst Upgrades and Downgrades

A number of research analysts have commented on RVTY shares. JPMorgan Chase & Co. upped their price target on Revvity from $155.00 to $160.00 and gave the company a “neutral” rating in a research report on Wednesday. Zacks Research raised shares of Revvity from a “strong sell” rating to a “hold” rating in a research report on Tuesday, August 4th. Cfra upgraded shares of Revvity from a “hold” rating to a “buy” rating in a report on Wednesday. TD Cowen upped their price objective on shares of Revvity from $175.00 to $185.00 and gave the stock a “buy” rating in a report on Wednesday. Finally, Barclays raised their target price on shares of Revvity from $160.00 to $175.00 and gave the stock an “equal weight” rating in a research report on Wednesday. Six analysts have rated the stock with a Buy rating and thirteen have assigned a Hold rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Hold” and a consensus price target of $133.86.

Revvity Company Profile

Revvity, Inc provides technology, products and services for the life sciences and diagnostics markets. The company supports pharmaceutical and biotechnology research, clinical laboratories and other healthcare organizations with tools used in drug discovery, biological research, disease detection and laboratory testing.

Its offerings include laboratory instruments, reagents, consumables, software and workflow solutions. Key areas include genomics, proteomics, cellular analysis, imaging, screening, automation and reproductive health, as well as newborn screening and other diagnostic applications.